C3 News

FDA Patient Listening Session on LGMDs held October 20, 2020

On October 20th, 2020, the LGMD community was able to meet with the FDA to share our patient experiences. This was a patient-led listening session organized by a consortium of advocacy organizations, including Coalition to Cure Calpain 3. The session

C3 is Increasing Scientific Collaboration to Fight LGMD2A/R1

Coalition to Cure Calpain 3 (C3) initiates scientific collaboration to bring the best minds together to fight limb-girdle muscular dystrophy type 2A (LGMD2A/R1). Working to cure LGMD2A/R1 requires connecting ideas, scientists, clinicians, patient groups and companies to elevate research to

C3 is Connecting Patients to Clinical Studies

Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) to clinical studies. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness, we

Building the First LGMD2A/R1 Patient Registry

Coalition to Cure Calpain 3 (C3) has launched the first and only limb-girdle muscular dystrophy type 2A (LGMD2A/R1) patient registry. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness,

Promising study identifies compound that improves muscle in LGMD2A/R1 mice

A new publication from Dr. Melissa Spencer’s laboratory at the University of California Los Angeles identifies a compound that mimics the effects of exercise in a mouse model of limb girdle muscular dystrophy type 2A (LGMD2A/R1). These studies may point

C3 is connecting patients with one another!

Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) with one another. In celebration of ten years of progress in our mission to fund research for a cure and raise global

C3 is Building Scientific Leadership

Coalition to Cure Calpain 3 is leading the charge to assemble the best scientific minds to solve limb-girdle muscular dystrophy type 2A (LGMD2A/R1). In celebration of ten years of progress in our mission to fund research for a cure and build

C3 is Putting LGMD on the Map!

Coalition to Cure Calpain 3 is putting limb-girdle muscular dystrophy type 2A (LGMD2A/R1) on the map! In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness, C3 is proud to

C3 Celebrates a Decade of Achievement

Coalition to Cure Calpain 3 (C3) has come a long way in ten years in driving science and awareness to treat limb girdle muscular dystrophy, type 2A (known as LGMD2A/R1, LGMD R1 Calpain 3 related, or calpainopathy). In celebration of ten

Patient Recruitment Underway for C3-Sponsored Natural History Study

The GRASP-LGMD is currently recruiting for a natural history study for individuals with mutations in CAPN3 (calpain 3). This study will inform the design of future therapeutic trials and a better understanding of the disease. Participants can now enroll at Virginia